Leveron&Nexovas
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2062  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (59 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed3061    
    Printed139    
    Emailed0    
    PDF Downloaded76    
    Comments [Add]    

Recommend this journal

 


 
INVITED COMMENTS
Year : 2006  |  Volume : 54  |  Issue : 1  |  Page : 63

Invited Comments


Department of Neurology, Johns Hopkins University, School of Medicine Path 509, 600 N. Wolfe St. Baltimore, MD, 21287, USA

Correspondence Address:
Ahmet Hoke
Department of Neurology, Johns Hopkins University, School of Medicine Path 509, 600 N. Wolfe St. Baltimore, MD, 21287
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions



How to cite this article:
Hoke A. Invited Comments. Neurol India 2006;54:63

How to cite this URL:
Hoke A. Invited Comments. Neurol India [serial online] 2006 [cited 2022 Dec 3];54:63. Available from: https://www.neurologyindia.com/text.asp?2006/54/1/63/24709


The accompanying article titled 'Erythropoietin preconditioning on hippocampus neuronal apoptosis following status epilepticus induced by Li-pilocarpine in rats through anti-caspase-3 expression' examines the neuroprotective role of erythropoietin (EPO) in epilepsy. In recent years, EPO and its receptor (EPOR) have been shown to be present in the nervous system and EPO is neuroprotective in models of a variety of neurological illnesses. These range from acute illnesses such as stroke and spinal cord injury to more chronic illnesses such as peripheral neuropathies.[1],[2] A Phase II clinical trial of EPO has been completed[3] and a larger multi-center Phase III trial of EPO in stroke is underway in Germany. The article by Wen and colleagues is the first demonstration that EPO may be of benefit in epilepsy. They use a standard animal model of seizure induction in rats and show that pre-treatment of the animals with EPO partially prevents development of seizures and seizure induced neuronal death in this model. However, this is probably the first step in a line of investigation to evaluate a potential therapeutic role for EPO in epilepsy. In most neuroprotective animal models, the investigators administer the neuroprotective drug first before the insult and then after the insult to mimic what would happen in patients. Unfortunately, this second step was not done in this study and will need to be done before one can be more confident of a potential therapeutic role for EPO in epilepsy. Furthermore, in most patients seizures are part of a chronic epileptic illness and potential utility of EPO needs to be tested in an animal model of chronic epilepsy. Having said that though, recombinant human EPO is relatively safe and can be used in the context of a clinical trial in status epilepticus patients if animal studies show benefit when EPO is given after the onset of seizure activity.

 
  References Top

1.H φke A, editor. Erythropoietin and the Nervous System. Springer: Boston; 2006. p. 1-223.  Back to cited text no. 1    
2.Lipton SA. Erythropoietin for neurologic protection and diabetic neuropathy. N Eng J Med 2004;350:2516-7.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.  Back to cited text no. 3  [PUBMED]  




 

Top
Print this article  Email this article
Previous article Next article
Online since 20th March '04
Published by Wolters Kluwer - Medknow